DICLOFENAC SODIUM | N022122 | HALEON US HOLDINGS LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Laboflex, Inc. FDA-2025-P-4911 Laboflex, Inc. submitted this ANDA Suitability Petition pursuant to section 505(j)(2)(C) of the FDC Act and 21 C.F.R. § 314.93, requesting FDA confirmation that Diclofenac Sodium Plaster 1% is suitable for submission in an Abbreviated New Drug Application. The proposed plaster dosage form differs fr | Suitability | 2025-10-08 | Open | Laboflex |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.